Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Vanguard Group Inc.

Vanguard Group Inc. raised its position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) by 0.1% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 4,220,037 shares of the company’s stock after purchasing an additional 3,956 shares during the period. Vanguard Group Inc. owned about 0.07% of Protagonist Therapeutics worth $162,893,000 at the end of the most recent reporting period.

Several other large investors also recently bought and sold shares of the company. FNY Investment Advisers LLC purchased a new stake in shares of Protagonist Therapeutics in the 4th quarter worth about $38,000. KBC Group NV raised its position in Protagonist Therapeutics by 54.4% during the fourth quarter. KBC Group NV now owns 2,093 shares of the company’s stock worth $81,000 after acquiring an additional 737 shares during the last quarter. Nisa Investment Advisors LLC lifted its holdings in shares of Protagonist Therapeutics by 10.4% in the fourth quarter. Nisa Investment Advisors LLC now owns 3,133 shares of the company’s stock valued at $121,000 after purchasing an additional 295 shares in the last quarter. Cibc World Markets Corp acquired a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at approximately $211,000. Finally, Caprock Group LLC acquired a new stake in shares of Protagonist Therapeutics in the fourth quarter valued at approximately $224,000. Institutional investors and hedge funds own 98.63% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on PTGX. Truist Financial upped their target price on Protagonist Therapeutics from $60.00 to $76.00 and gave the company a “buy” rating in a research note on Tuesday, March 11th. JMP Securities restated a “market outperform” rating and issued a $58.00 price objective on shares of Protagonist Therapeutics in a research report on Friday, February 7th. BMO Capital Markets lifted their price objective on Protagonist Therapeutics from $62.00 to $72.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 11th. JPMorgan Chase & Co. boosted their target price on shares of Protagonist Therapeutics from $53.00 to $57.00 and gave the company an “overweight” rating in a research note on Tuesday, March 4th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $54.00 price target on shares of Protagonist Therapeutics in a research note on Monday, March 10th. Two analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $62.56.

Protagonist Therapeutics Price Performance

PTGX opened at $44.44 on Monday. Protagonist Therapeutics, Inc. has a 12 month low of $24.22 and a 12 month high of $60.60. The business has a 50-day moving average of $43.48 and a two-hundred day moving average of $42.91. The stock has a market capitalization of $2.73 billion, a price-to-earnings ratio of 16.71 and a beta of 2.30.

Protagonist Therapeutics (NASDAQ:PTGX) last released its earnings results on Friday, February 21st. The company reported $1.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.09) by $2.07. The firm had revenue of $170.64 million during the quarter, compared to the consensus estimate of $56.65 million. Protagonist Therapeutics had a net margin of 52.76% and a return on equity of 34.68%. Equities research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.43 earnings per share for the current year.

Insider Transactions at Protagonist Therapeutics

In related news, insider Arturo Md Molina sold 30,514 shares of the firm’s stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $55.74, for a total value of $1,700,850.36. Following the transaction, the insider now owns 83,892 shares in the company, valued at approximately $4,676,140.08. This trade represents a 26.67 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, Director William D. Waddill sold 4,000 shares of the business’s stock in a transaction that occurred on Monday, March 17th. The stock was sold at an average price of $54.25, for a total transaction of $217,000.00. Following the sale, the director now owns 13,130 shares of the company’s stock, valued at approximately $712,302.50. This represents a 23.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 64,776 shares of company stock worth $3,585,010 in the last ninety days. Insiders own 5.40% of the company’s stock.

About Protagonist Therapeutics

Protagonist Therapeutics, Inc, a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis.